GlassScriptPhysician profile
Laura Dominguez
NPI 1649407925
$3,249.83
in general payments reported to CMS, 2019-2025
20 companies · $2,597 in 2025
The $2,597 reported for 2025 was more than what 92% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.80 · 2020: $14.82 · 2021: $37.65 · 2024: $581 · 2025: $2,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,348 · Travel and Lodging: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,348.45 |
| Travel and Lodging | $830.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $1,652.62 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $265.83 | 2024-2025 | Dupixent |
| Genzyme Corporation | $261.76 | 2024-2025 | |
| Integra Lifesciences Corporation | $223.97 | 2024-2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Neurent Medical Limited | $189.05 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark System, Neuromark Device |
| Glaxosmithkline, LLC. | $134.45 | 2024-2025 | Nucala |
| Smith+Nephew, INC. | $120.24 | 2024 | Halo, Coblation, Tula |
| Phathom Pharmaceuticals, INC. | $63.35 | 2024-2025 | Voquezna |
| Steris Corporation | $60.91 | 2025 | |
| Optinose US, INC. | $46.82 | 2024-2025 | |
| Medtronic, INC. | $37.98 | 2024-2025 | Stealthstation S8 Platform |
| Hikma Pharmaceuticals USA | $33.70 | 2025 | Ryaltris |
| Alk-Abello, INC | $31.80 | 2025 | Neffy, Grastek, Ragwitek |
| Stryker Corporation | $25.47 | 2025 | Clarifix |
| Agiliti Surgical, INC. | $24.44 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $18.80 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $15.77 | 2025 | Iqirvo |
| Astrazeneca Pharmaceuticals LP | $14.84 | 2025 | Tezspire |
| Freudenberg Medical, LLC | $14.82 | 2020 | |
| Pentax of America, INC. | $13.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Dominguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.